Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ipatasertib|DRUG: Fulvestrant|OTHER: Placebo
Sponsor: Canadian Cancer Trials Group
Collaborators: Hoffmann-La Roche